Table 5.
Association study of TLR7 SNPs with clinical characteristics of SLEa
| SLE total | Anti-Sm antibodies | Anti-dsDNA antibodies | Renal disorder | ||||||
|---|---|---|---|---|---|---|---|---|---|
| SNP | Model | P | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) |
| rs3853839 | Allele | 0.017 | 1.36 (1.06 to 1.75) | 0.032 | 1.65 (1.04 to 2.62) | 0.014 | 1.40 (1.07 to 1.84) | 0.025 | 1.40 (1.04 to 1.89) |
| rs179019 | Recessive | 0.016b | 2.02 (1.15 to 3.54) | 1.0b | 0.89 (0.29 to 2.73) | 0.029b | 1.93 (1.07 to 3.48) | 0.011b | 2.25 (1.21 to 4.18) |
| rs179010 | Recessive | 0.018 | 1.75 (1.10 to 2.80) | 0.67b | 1.16 (0.51 to 2.67) | 0.030 | 1.72 (1.05 to 2.83) | 0.042 | 1.73 (1.02 to 2.95) |
aTLR7, Toll-like receptor 7 gene; SNP, single-nucleotide polymorphism; SLE, systemic lupus erythematosus; anti-Sm, anti-Smith; dsDNA, double-stranded DNA; OR, odds ratio, 95% CI, confidence interval; bFisher's exact test was used. Association was tested by χ2 analysis or Fisher's exact test using 2 × 2 contingency tables under the indicated model for rs3853839G, rs179019A and rs179010 T allele. All SLE as well as each SLE subset were compared with healthy controls.